Chief Executive Officer
Mr. Aselage has been Chief Executive Officer (CEO) since November 2014 and a member of the Board of Directors of Retrophin, Inc. since 2012. During his tenure as CEO, Mr. Aselage has drawn upon more than 30 years of biopharmaceutical experience to lead the transformation of Retrophin. Following his appointment, Mr. Aselage solidified the Company's leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders.
Prior to his appointment, Mr. Aselage was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi ) and Bristol Laboratories. Mr. Aselage is a member of the Board of Directors for Acer Therapeutics and Patara Pharma. Mr. Aselage received his B.S. in Biology from the University of Notre Dame, and currently serves on the Advisory Council for the Department of Science at Notre Dame.
Chief Operating Officer
Mr. McFarlane has served as Chief Operating Officer of Retrophin, Inc. since August 2016. Mr. McFarlane is responsible for the Company's daily operations with principal responsibility for several key functions, including commercial operations, business development, patient services, and program management. Prior to joining Retrophin, Mr. McFarlane held leadership roles at leading biopharmaceutical companies, including UCB Inc., Genzyme Inc., and Sangstat Medical Corporation. Most recently, Mr. McFarlane served as Vice President of UCB, where he was responsible for the Global Bone Business in collaboration with Amgen. Mr. McFarlane also served as Vice President and General Manager of the U.S. Immunology Business during his tenure at UCB. This was preceded by positions of increasing responsibility while at Genzyme and Sangstat. Mr. McFarlane served as an officer and enlisted soldier in the United States Army Reserves. Mr. McFarlane received his B.S. and M.S. in Nursing from the University of Florida.
Laura M. Clague, CPA
Chief Financial Officer
Ms. Clague has served as Chief Financial Officer of Retrophin, Inc. since November 2014. Ms. Clague has 30 years of experience as a financial executive, and oversees the Company’s Accounting, Finance, IT and Facilities functions. Previously, Ms. Clague served as Chief Financial Officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. Prior to the acquisition, Ms. Clague was the Vice President, Corporate Controller and Principal Accounting Officer of Amylin for 10 years, when she also served as the Chief Financial Officer of Amylin's collaboration with Eli Lilly and Company. Earlier, Ms. Clague held financial roles at Sony Electronics, Inc., Cubic Corporation and KPMG. Ms. Clague currently serves on the board of directors of LRAD Corporation. Ms. Clague is a Certified Public Accountant in the State of California, and received a B.S. in Business Administration from Menlo College.
Noah L. Rosenberg, MD
Chief Medical Officer
Dr. Rosenberg has served as Chief Medical Officer of Retrophin since July 2018 and is responsible for overseeing the clinical development of the Company's product pipeline. He brings more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization. Previously, Dr. Rosenberg served as chief medical officer at Medimetriks Pharmaceuticals where he was responsible for the clinical development and medical strategy for pipeline candidates and multiple product launches. He also served as chief medical officer of Esperion Therapeutics, where he led the design, protocol implementation, execution and monitoring of innovative clinical programs. Prior to joining Esperion, Dr. Rosenberg served as the executive director and head of cardiovascular and metabolism clinical development for the Forest Research Institute, where he led the advancement of multiple late-stage clinical trials. Earlier in his career, he held leadership roles in clinical development, medical affairs and administration at Sanofi Aventis and Pfizer. Dr. Rosenberg completed his internal medicine residency at The Icahn School of Medicine at Mount Sinai Hospital and holds an M.D. from the Drexel University College of Medicine and a B.A. from Johns Hopkins University.
William "Bill" Rote, PhD
SVP, Research and Development
Dr. Rote has served as senior vice president of Research & Development (R&D) of Retrophin, Inc. since February 2017. He is responsible for all aspects of the Company's R&D functions, overseeing clinical development, discovery and translational research, regulatory affairs, and medical affairs. Prior to joining Retrophin, Dr. Rote led clinical development at Ardea Biosciences, a wholly owned subsidiary of AstraZeneca. In this role, he was responsible for leading all aspects of clinical trial execution and analysis, including clinical operations, data management, and biostatistics. Prior to his role at Ardea, Dr. Rote held numerous positions of increasing responsibility at Amylin, including vice president and site head for R&D. He earned both his Ph.D. in Pharmacology and B.S. in Pre-Medicine from Pennsylvania State University, and received postdoctoral training from the University of Michigan.
General Counsel and Corporate Secretary
Ms. Reed has served as Senior Vice President, General Counsel and Corporate Secretary of Retrophin, Inc. since January 2017. She is responsible for overseeing the Company's general legal, intellectual property, government affairs and corporate compliance functions. Previously, Ms. Reed served as General Counsel of Celladon Corporation, and prior to Celladon, served as General Counsel of Anadys Pharmaceuticals, Inc. until Anadys' acquisition by Roche. Prior to joining Anadys, she was an attorney with the law firms Cooley Godward LLP and Brobeck, Phleger & Harrison LLP. Ms. Reed is a member of the State Bar of California, and received her J.D. from Harvard Law School and her B.S. in Business Administration from the University of California at Berkeley.